Hong Kong-based Agilis Robotics Ltd has successfully completed a second round of live animal testing using its proprietary surgical robotic system. The test, conducted by Dr. Jason Y.K. Chan, co-founder of Agilis Robotics, utilized the company’s second-generation device to remove artificial tumors from a live pig specimen using the en-bloc resection of bladder tumor (ERBT) technique. The results demonstrated the system’s accuracy, safety, and efficacy, meeting expectations and highlighting its potential for future clinical applications.
Agilis Robotics System: Features and Improvements
The Agilis Robotics system is a surgical robotic solution designed for endoscopic surgery, featuring flexible surgical robotic instruments, a positioning cart, and a surgeon’s control chair. The instruments, with a diameter of less than 2.8 mm, are capable of gripping and cutting away tumor tissue to remove it entirely. The second-generation prototype used in the test includes several improvements over the original system, such as a smaller footprint. The updated positioning cart is 50% smaller, making it highly compact and easier to position in the operating room. The third-generation prototype is currently in the preparation phase, with the first-in-human trial expected within the next two years.
Funding and Future Plans
Agilis Robotics, which successfully completed a Series A funding round in June 2022, is now preparing for a Series B financing round with a target of at least USD 10 million. The company is currently valued at USD 100 million. The funding will support the development and commercialization of its surgical robotic system, aiming to bring advanced robotic surgery solutions to the market.-Fineline Info & Tech
